- Tuesday, April 5, 2022
- IPC GENERAL
- Industry, Research, Treatment
New data presented by Amgen at the 2022 AAD Congress reinforced the efficacy of apremilast in patients with mild to moderate plaque psoriasis and in patients with palmoplantar pustulosis. This announcement follows the recent US Food and Drug Administration (FDA) expanded Otezla label approval which enabled the use of Otezla across all levels of disease severity. Otezla is the first and only oral therapy FDA approved in adult patients with mild, moderate, and severe plaque psoriasis.
